Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**mesofiller + mesotox** is a sterile, injectable, gel-based dermal filler used for temporary correction of small skin defects such as wrinkles or scars, primarily in the upper part of the face. It combines cross-linked hyaluronic acid of non-animal origin (produced via bacterial fermentation) with botulinum toxin in high dilution, alongside other mesotherapeutic ingredients. The formulation is administered intradermally or subcutaneously and works by providing hydration, volume, and subtle reduction of fine lines, sebum production, and pores, while maintaining the natural musculature of the face. The use of botulinum toxin at low concentrations allows for skin quality improvement without the “frozen” look typical of standard botox injections, while cross-linked hyaluronic acid acts as the primary filling agent. The product is designed for aesthetic purposes and is not intended for the treatment of disease. Its effects typically last for 3-6 months, with onset seen in several days[2][1][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mesofiller + mesotox.